small molecule

ORFADIN

NITISINONE

Loss of exclusivityloss of exclusivity
CompanySWEDISH ORPHAN BIOVITRUM AB PUBL

Drug detail

Brand nameORFADIN
Active ingredientNITISINONE
Strength5MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2002
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ORFADIN patent cliff — loss of exclusivity — | CliffBio